PRMT5 and cancer: Importantly, MTAP loss determines the accumulation of the MTA substrate, a natural inhibitor of protein arginine methyltransferase 5 (PRMT5), thus generating a hypomorphic PRMT5 state in MTAP‐deficient cancers that are, in this way, selectively sensitized to further PRMT5 inhibition.